Entrepreneurship, Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… the start-up DETERA Therapeutics is developing a drug candidate for crescentic glomerulonephritis (CGN). This … work carried out at the Chemical Biology Laboratory of the Department of Medicines and Health Technologies (MTS … to manage several biotechnology companies for more than ten years. With DETERA Therapeutics, the trio targets kidney …Published on: